文献速递免疫规划传染病防控与疫情报告

HIV感染者接种SARS-CoV-2疫苗CoronaVac或BNT162b2或CoronaVac/BNT162b2加强序贯后的体液免疫应答:一项横断面研究

Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
PubMed 文献 · Vaccine · 2023-12-20

该横断面研究纳入189名参与者(161例HIV感染者),比较CoronaVac与BNT162b2接种后4-6个月的体液免疫应答。无既往COVID-19的HIV感染者中,CoronaVac组抗S蛋白抗体中位数显著低于BNT162b2组(32 U/mL vs 587 U/mL,p<0.001),中和抗体阳性率亦较低(30% vs 93%,p<0.001)。加强序贯接种显著提高抗体水平,既往COVID-19及CD4+计数<200 cells/mL影响免疫应答。

要点

  • HIV感染者接种CoronaVac后抗S蛋白抗体和中和抗体阳性率均显著低于BNT162b2。
  • CoronaVac/BNT162b2加强序贯在HIV感染者和HIV阴性对照中均显著提高抗体滴度。
  • CD4+计数<200 cells/mL的HIV感染者对两种疫苗的免疫应答均较弱。

核心结论

  • CoronaVac在HIV感染者和HIV阴性对照中诱导的体液免疫应答均弱于BNT162b2,尤其在无既往COVID-19的免疫抑制HIV感染者中。
  • 混合免疫和异源加强接种可提高抗体水平。

研究设计与样本

  • 横断面研究,纳入189名参与者,其中161名(85%)为HIV感染者,其余为HIV阴性对照。
  • 参与者接种CoronaVac或BNT162b2,部分亚组接受CoronaVac/BNT162b2加强序贯。
  • 初次接种后4-6个月采集血样,使用经验证的检测方法测定抗SARS-CoV-2 S蛋白抗体(aSAb)和中和抗体(NtAb)。
  • 按年龄、性别、既往COVID-19史和CD4+细胞计数评估免疫应答。

主要发现

  • 无已知既往COVID-19的参与者中,接种CoronaVac的HIV感染者aSAb中位数显著低于接种BNT162b2者(32 U/mL vs 587 U/mL,p<0.001),HIV阴性对照中结果相似。
  • CoronaVac接种后NtAb阳性率显著低于BNT162b2(30% vs 93%,p<0.001)。
  • 加强序贯组中,HIV感染者和HIV阴性对照的aSAb滴度均显著升高(从33 U/mL升至2500 U/mL,p<0.001)。
  • 加强序贯后,HIV感染者NtAb阳性率从20%升至95%,HIV阴性对照从27%升至100%。
  • 既往COVID-19使接种后抗体滴度显著升高,尤其在BNT162b2组。

关键数值与推荐

  • 无既往COVID-19的HIV感染者:CoronaVac组aSAb中位数32 U/mL vs BNT162b2组587 U/mL(p<0.001)。
  • 无既往COVID-19的HIV感染者:CoronaVac组NtAb阳性率30% vs BNT162b2组93%(p<0.001)。
  • 加强序贯组:aSAb滴度从33 U/mL升至2500 U/mL(p<0.001)。
  • 加强序贯后HIV感染者NtAb阳性率从20%升至95%,HIV阴性对照从27%升至100%。
  • CD4+计数<200 cells/mL的HIV感染者对两种疫苗的免疫应答均较弱。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evidence of SARS-CoV-2 vaccine effectiveness in people living with HIV (PLWH) is limited. This study evaluated the humoral immune response to CoronaVac™ (virus inactivated) and BNT162b2 (mRNA- based) vaccines in PLWH and HIV-negative controls, with and without a booster sequence. METHODS: We conducted a cross-sectional study on PLWH and HIV-negative controls who received CoronaVac or BNT162b2, with a subgroup receiving a CoronaVac/BNT162b2 booster. Blood samples were collected 4-6 months after primary vaccination and tested for anti-SARS-CoV-2 protein S (aSAb) and neutralizing antibodies (NtAb) using validated assays. Immune response was evaluated by age, sex, previous COVID-19 history, and CD4 + cell count. FINDINGS: One hundred and eighty nine participants were enrolled with 161 (85%) being PLWH. Among participants without previous known COVID-19, median aSAb levels were significantly lower in PLWH who received CoronaVac compared to BNT162b2 (32 U/mL vs. 587 U/mL, p < 0.001), with similar results in HIV-negative controls. NtAb presence was also significantly lower after CoronaVac compared to BNT162b2 (30% vs. 93%, p < 0.001). The booster sequence group showed a significant increase in aSAb titers in both PLWH and HIV-negative controls (from 33 U/ml to 2500 U/ml, p < 0.001), and NtAb positivity increased from 20% to 95 % in PLWH, and 27% to 100% in HIV-negative controls. Prior COVID-19 led to significantly higher post-vaccine antibody titers particularly in the BNT162b2 group. PLWH with CD4 + count < 200 cells/mL showed a weaker immune response to both vaccines. INTERPRETATION: CoronaVac resulted in a weaker immune response in both PLWH and HIV-negative controls compared to BNT162b2, particularly in immunosuppressed PLWH without prior COVID-19. Hybrid immunity and heterologous booster vaccination increased antibody levels. FUNDING: Local funding.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wolff M, Charpentier P, Canals A, et al. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study. Vaccine. 2023. PMID: 38123398. doi:10.1016/j.vaccine.2023.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。